- Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m
- Strong growth momentum in the Pharma segment
- EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.; all business units contributing
- Free cash flow €63m, +11% above 2024’s high benchmark
- H1 Book-to-Bill at 117%, signaling strong foundation for future growth
- 2025 outlook: sustained sales growth and continued margin expansion
Stuttgart (Germany), September 02, 2025 – The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported strong results for the first half year of 2025 compared to the prior year. Driven by the growth-focused strategy launched in 2024, the Group delivered double-digit sales growth, significantly higher profitability, and strong free cash flow, while continuing to advance on its strategic agenda.
“The first half of 2025 demonstrates the strength of our strategy, our ability to execute and our commitment to helping customers succeed by being a strategic lifecycle partner,” says Torsten Türling, CEO of Syntegon. “With strong order intake and top line growth, improved margins across all business units, and continued operational efficiency gains, Syntegon is well on track to deliver another year of record results.”
Consistent growth and profitability improvement supported by diversified portfolio
In first half of 2025, driven by the strong momentum in its Pharma segment, Syntegon achieved sales of €824m, +11% growth compared to prior year. Continued expansion in the biologics segment and increasingly stringent regulatory requirements are fueling sustained high order intake for Syntegon’s aseptic, isolator-equipped Fill & Finish line solutions. The Food business delivered strong margin expansion, reflecting the rising success of the new SVX product line and efficiency improvements across the entire Food business.
EBITDA reached €127m, an increase of +41% vs the same period of 2024, driven by sales growth and strong margin expansion, resulting in an H1 EBITDA margin of 15.5%. Margins expanded thanks to higher volumes in higher-margin projects, disciplined project execution and faster-than-expected synergies from the Telstar acquisition.
Potential headwinds from global trade developments, particularly U.S. tariffs, are being mitigated through swift measures, Syntegon’s globally balanced supply chain, and strong partnerships with customers. The company anticipates minimal impact in 2025.
Eros Carletti, CFO of Syntegon said: “In the first half of 2025, we delivered strong improvements across all financial metrics. Our value creation program and disciplined execution are translating into continued higher margins and sustainable cash flow, providing the foundation for further growth and investment in the nearest future.”
Syntegon showcases innovation leadership with SynTiso launch
Syntegon is a key strategic partner to the global Pharma, Biotech and Food sectors. At its Pharmatag event in May 2025, Syntegon welcomed a record 350 customers from across the global pharma and biotech sectors. The event featured the world premiere and launch of SynTiso, a groundbreaking innovative gloveless, highly autonomous RTU line solution for liquid pharmaceutical filling developed jointly with two customers. SynTiso is fully Annex 1 compliant and offers unmatched drug dosage flexibility. SynTiso underlines Syntegon’s leading technology and innovation capabilities. The first customer delivery is expected in 2026.
Syntegon’s Pharma business has experienced strong growth momentum
Outlook 2025
With a solid order book, Syntegon is confident in sustaining growth momentum and delivering further margin improvements in the second half of 2025.
Get inspired with regular updates on technologies and services, case studies, webinar offers and events.
